Other Media Coverage

Filter by year

2019
2019
Aug 07, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy
Mutation-derived neoantigens distinguish tumor from normal cells. T cells can sense the HLA-presented mutations, recognize tumor cells as non-self and destroy them.
2019
Jun 07, 2019
Agenus’ COO Speaks on the Next Level of Immuno-Oncology
At an Education Session, Jennifer Buell, chief operating officer of Agenus, spoke on the trends and obstacles in immuno-oncology.
2019
Apr 18, 2019
Agenus scales the AI ALPS
Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data.
2019
Apr 01, 2019
Garo Armen And Audacity At Agenus
What motivates a biopharma executive — a company founder, chair, CEO, or any other leader in the organization? In many industries and lines of business, where the sale of goods paves the simplest path to wealth, the prospect of great riches may be the only incentive needed.
2019
Jan 30, 2019
Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot
Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.
2019
Jan 29, 2019
This Small Biotech Company Is Doing Its Own Digital Offering
In a novel approach for the biotechnology industry, small-cap company Agenus Inc. is aiming to raise $50 million to $100 million by issuing digital securities backed by future sales of an experimental cancer drug.
2019
Jan 29, 2019
Agenus touts blockchain tech to roll out new ‘digital security’ for its PD-1, but will it work?
Beset with setbacks, a once cash-poor Agenus had something to cheer late last year when behemoth Gilead signed on as a partner on up to five of its immuno-oncology programs. On Tuesday, the biotech offered investors an intriguing proposal: fund the development of a single drug, while preserving shareholder equity.
2019
Jan 29, 2019
Fintech And Biotech Are Coming Together To Transform Drug Development
Today, fintech and biotech are coming together to create a new, targeted financing option that is intended to drive efficiencies and advantages in drug development.
2018
2018
Dec 20, 2018
Lexington biotech Agenus signs drug development deal with Gilead
Agenus has signed a deal with California-based Gilead Sciences that will pay the Lexington biotech $150 million to help develop and market up to five drugs to treat cancer by taking advantage of the body’s own immune system.
2018
Dec 20, 2018
Gilead Sciences Commits $150M to Agenus in Cancer Drug R&D Pact
Xconomy San Francisco — For the second time this week, Gilead Sciences has partnered with a Boston-area biotech, this time with a deal that covers up to five experimental cancer immunotherapies being developed by Agenus.

Get In Touch

Call us with questions or submit a partner request.

Call Us: 781.674.4400 Submit a Request